BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31038470)

  • 1. Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1.
    Chamseddin BH; Hernandez L; Solorzano D; Vega J; Le LQ
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31038470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous neurofibromas: Current clinical and pathologic issues.
    Ortonne N; Wolkenstein P; Blakeley JO; Korf B; Plotkin SR; Riccardi VM; Miller DC; Huson S; Peltonen J; Rosenberg A; Carroll SL; Verma SK; Mautner V; Upadhyaya M; Stemmer-Rachamimov A
    Neurology; 2018 Jul; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey.
    Guiraud M; Bouroubi A; Beauchamp R; Bocquet A; Grégoire JM; Rauly-Lestienne I; Blanco I; Wolkenstein P; Schmitt AM
    Orphanet J Rare Dis; 2019 Dec; 14(1):286. PubMed ID: 31801570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials.
    Thalheimer RD; Merker VL; Ly KI; Champlain A; Sawaya J; Askenazi NL; Herr HP; Da JLW; Jordan JT; Muzikansky A; Pearce EM; Sakamoto FH; Blakeley JO; Anderson RR; Plotkin SR;
    Neurology; 2021 Aug; 97(7 Suppl 1):S32-S41. PubMed ID: 34230197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study.
    Cannon A; Chen MJ; Li P; Boyd KP; Theos A; Redden DT; Korf B
    Orphanet J Rare Dis; 2018 Feb; 13(1):31. PubMed ID: 29415745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and clinicopathological characteristics of lipomatous neurofibromas in neurofibromatosis 1: An investigation of 229 cutaneous neurofibromas and a systematic review of the literature.
    Rozza-de-Menezes RE; Brum CAI; Gaglionone NC; de Sousa Almeida LM; Andrade-Losso RM; Paiva BVB; Faveret PLS; da Silva AV; Siqueira OHK; Riccardi VM; Cunha KS
    J Cutan Pathol; 2018 Oct; 45(10):743-753. PubMed ID: 29959804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cosmetic and functional results after resection of cutaneous neurofibroma in neurofibromatosis type 1 : Operation of neurofibroma improves quality of life while having moderate complications].
    Walz B; Pfefferle V; Häfner HM; Kofler L
    Dermatologie (Heidelb); 2022 Dec; 74(12):961-968. PubMed ID: 37728798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
    Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
    PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience.
    Peltonen S; Jannic A; Wolkenstein P
    Eur J Med Genet; 2022 Jan; 65(1):104386. PubMed ID: 34768015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head circumference and anthropometric changes and their relation to plexiform and skin neurofibromas in sporadic and familial neurofibromatosis 1 Brazilian adults: a cross-sectional study.
    Basto DL; de Souza Vieira G; Andrade-Losso RM; Almeida PN; Riccardi VM; Rozza-de-Menezes RE; Cunha KS
    Orphanet J Rare Dis; 2022 Sep; 17(1):341. PubMed ID: 36064430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
    Maguiness S; Berman Y; Rubin N; Dodds M; Plotkin SR; Wong C; Moertel C;
    Neurology; 2021 Aug; 97(7 Suppl 1):S25-S31. PubMed ID: 34230204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods.
    Richey P; Funk M; Sakamoto F; Plotkin S; Ly I; Jordan J; Muzikansky A; Roberts J; Farinelli W; Levin Y; Garibyan L; Blakeley JO; Anderson RR
    J Am Acad Dermatol; 2024 Apr; 90(4):767-774. PubMed ID: 38086517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and Emerging Imaging Techniques for Neurofibromatosis Type 1-Associated Cutaneous Neurofibromas.
    Li Y; Blakeley JO; Ly I; Berman Y; Lau J; Wolkenstein P; Bergqvist C; Jia W; Milner TE; Katta N; Durkin AJ; Kennedy GT; Rowland R; Romo CG; Fleming J; Kelly KM
    J Invest Dermatol; 2023 Aug; 143(8):1397-1405. PubMed ID: 37330718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of electrodessication in the treatment of cutaneous neurofibromatosis: A retrospective patient satisfaction outcome assessment.
    Lutterodt CG; Mohan A; Kirkpatrick N
    J Plast Reconstr Aesthet Surg; 2016 Jun; 69(6):765-769. PubMed ID: 27105548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.
    Jiang C; McKay RM; Lee SY; Romo CG; Blakeley JO; Haniffa M; Serra E; Steensma MR; Largaespada D; Le LQ
    J Invest Dermatol; 2023 Aug; 143(8):1369-1377. PubMed ID: 37318402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin.
    Rice FL; Houk G; Wymer JP; Gosline SJC; Guinney J; Wu J; Ratner N; Jankowski MP; La Rosa S; Dockum M; Storey JR; Carroll SL; Albrecht PJ; Riccardi VM
    PLoS One; 2019; 14(5):e0216527. PubMed ID: 31107888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denervation in von Recklinghausen's neurofibromatosis (NF-1) leads to fewer and smaller neurofibromas.
    Riccardi VM; Powell PP
    Neurology; 1988 Nov; 38(11):1810. PubMed ID: 3141830
    [No Abstract]   [Full Text] [Related]  

  • 18. Electrosurgical excision technique for the treatment of multiple cutaneous lesions in neurofibromatosis type I.
    Levine SM; Levine E; Taub PJ; Weinberg H
    J Plast Reconstr Aesthet Surg; 2008 Aug; 61(8):958-62. PubMed ID: 17531563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical assessment of the use of topical liquid diclofenac following laser microporation of cutaneous neurofibromas in individuals with neurofibromatosis type 1.
    Oliveira LB; Geller M; Cunha KS; Santos A; Bernacchi A; Rubenstein AE; Takirambudde S; Mezitis S; de Almeida Ito Brum C; Darrigo LG; Ribeiro MG
    Heliyon; 2021 Mar; 7(3):e06518. PubMed ID: 33817379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI.
    Ly KI; Merker VL; Cai W; Bredella MA; Muzikansky A; Thalheimer RD; Da JL; Orr CC; Herr HP; Morris ME; Chang CY; Harris GJ; Plotkin SR; Jordan JT
    Neurology; 2023 Feb; 100(7):e661-e670. PubMed ID: 36332985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.